Long-term survival based on pathologic response to neoadjuvant therapy in esophageal cancer

被引:24
作者
Tiesi, Gregory [1 ]
Park, Wungki [2 ]
Gunder, Meredith [1 ]
Rubio, Gustavo [1 ]
Berger, Michael [1 ]
Ardalan, Bach [2 ]
Livingstone, Alan [1 ]
Franceschi, Dido [1 ]
机构
[1] Univ Miami, Miller Sch Med, Div Surg Oncol,Dept Gen Surg,Univ Miami Hosp, Jackson Mem Hosp,Sylvester Comprehens Canc Ctr, Miami, FL 33136 USA
[2] Univ Miami, Miller Sch Med, Sylvester Comprehens Canc Ctr,Univ Miami Hosp, Div Hematol Oncol,Dept Med,Jackson Mem Hosp, Miami, FL 33136 USA
关键词
Esophageal neoplasm; Neoadjuvant treatment; PERIOPERATIVE CHEMOTHERAPY; SURGERY; CHEMORADIOTHERAPY; CARCINOMA; TRIAL; CHEMORADIATION; ADENOCARCINOMA; RADIOTHERAPY;
D O I
10.1016/j.jss.2017.03.022
中图分类号
R61 [外科手术学];
学科分类号
摘要
Background: Neoadjuvant treatment is standard for locally advanced esophageal cancer. However, whether the addition of radiation to neoadjuvant regimen improves survival remains unclear. The aim of this study was to compare survival in locally advanced esophageal cancer treated with neoadjuvant chemotherapy versus chemoradiation. Materials and methods: A prospectively maintained database of esophagectomies (1999-2012) was analyzed. We identified 297 patients with locally advanced esophageal cancer that underwent either neoadjuvant chemotherapy (n = 231) or chemoradiation (n = 66) followed by esophagectomy. Pretreatment and pathologic staging were compared to assess response. Overall survival was recorded. Results: Most patients in the chemotherapy and chemoradiation groups had pretreatment stage III disease (66.7% versus 65.2%; P = 0.44). Median follow-up was 79.3 and 64.9 mo for chemotherapy and chemoradiation cohorts, respectively. Complete response rate was higher in chemoradiation than chemotherapy groups (30.3% versus 13.8%; P < 0.001). Overall survival was similar between complete responders in both groups (median not reached versus 121.1 mo; chemotherapy versus chemoradiation). However, partial responders in the chemotherapy cohort had improved median survival (147.2 mo) versus those in the chemoradiation cohort (83.7 mo, P < 0.03). Within the chemotherapy-only group, partial responders had improved survival compared with nonresponders (P = 0.041); however, there was no difference in survival between partial and complete responders (P = 0.36). Conclusions: In patients undergoing esophagectomy for locally advanced esophageal cancer, neoadjuvant chemotherapy was associated with an equivalent overall survival, when compared with neoadjuvant chemoradiotherapy. Adding neoadjuvant radiation may enhance complete response rates but does not appear to be associated with improved survival. (C) 2017 Elsevier Inc. All rights reserved.
引用
收藏
页码:65 / 72
页数:8
相关论文
共 32 条
[1]   Esophageal and Esophagogastric Junction Cancers, Version 1.2015 [J].
Ajani, Jaffer A. ;
D'Amico, Thomas A. ;
Almhanna, Khaldoun ;
Bentrem, David J. ;
Besh, Stephen ;
Chao, Joseph ;
Das, Prajnan ;
Denlinger, Crystal ;
Fanta, Paul ;
Fuchs, Charles S. ;
Gerdes, Hans ;
Glasgow, Robert E. ;
Hayman, James A. ;
Hochwald, Steven ;
Hofstetter, Wayne L. ;
Ilson, David H. ;
Jaroszewski, Dawn ;
Jasperson, Kory ;
Keswani, Rajesh N. ;
Kleinberg, Lawrence R. ;
Korn, W. Michael ;
Leong, Stephen ;
Lockhart, A. Craig ;
Mulcahy, Mary F. ;
Orringer, Mark B. ;
Posey, James A. ;
Poultsides, George A. ;
Sasson, Aaron R. ;
Scott, Walter J. ;
Strong, Vivian E. ;
Varghese, Thomas K., Jr. ;
Washington, Mary Kay ;
Willett, Christopher G. ;
Wright, Cameron D. ;
Zelman, Debra ;
McMillian, Nicole ;
Sundar, Hema .
JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK, 2015, 13 (02) :194-227
[2]   Long-Term Results of a Randomized Trial of Surgery With or Without Preoperative Chemotherapy in Esophageal Cancer [J].
Allum, William H. ;
Stenning, Sally P. ;
Bancewicz, John ;
Clark, Peter I. ;
Langley, Ruth E. .
JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (30) :5062-5067
[3]   Neoadjuvant, surgery and adjuvant chemotherapy without radiation for esophageal cancer [J].
Ardalan, Bach ;
Spector, Seth A. ;
Livingstone, Alan S. ;
Franceschi, Dido ;
Mezentsev, Dmitry ;
Lima, Mayra ;
Bowen-Wells, Carol P. ;
Sparling, Lynne ;
Avisar, Eli ;
Sapp, Michelle ;
Rios, Joyce ;
Walker, Gail ;
Ganjei-Azar, Parvin .
JAPANESE JOURNAL OF CLINICAL ONCOLOGY, 2007, 37 (08) :590-596
[4]   Refining esophageal cancer staging after neoadjuvant therapy: Importance of treatment response [J].
Barbour, Andrew P. ;
Jones, Mark ;
Gonen, Mithat ;
Gotley, David C. ;
Thomas, Janine ;
Thomson, Damien B. ;
Burmeister, Bryan ;
Smithers, B. Mark .
ANNALS OF SURGICAL ONCOLOGY, 2008, 15 (10) :2894-2902
[5]   Chemotherapy followed by surgery versus surgery alone in patients with resectable oesophageal squamous cell carcinoma: Long-term results of a randomized controlled trial [J].
Boonstra, Jurjen J. ;
Kok, Tjebbe C. ;
Wijnhoven, Bas P. L. ;
van Heijl, Mark ;
Henegouwen, Mark I. van Berge ;
ten Kate, Fiebo J. W. ;
Siersema, Peter D. ;
Dinjens, Winand N. M. ;
van Lanschot, Jan J. B. ;
Tilanus, Hugo W. ;
van der Gaast, Ate .
BMC CANCER, 2011, 11
[6]   Chemoradiotherapy followed by surgery compared with surgery alone in squamous-cell cancer of the esophagus [J].
Bosset, JF ;
Gignoux, M ;
Triboulet, JP ;
Tiret, E ;
Mantion, G ;
Elias, D ;
Lozach, P ;
Ollier, JC ;
Pavy, JJ ;
Mercier, M ;
Sahmoud, T .
NEW ENGLAND JOURNAL OF MEDICINE, 1997, 337 (03) :161-167
[7]   Surgery alone versus chemoradiotherapy followed by surgery for resectable cancer of the oesophagus: a randomised controlled phase III trial [J].
Burmeister, BH ;
Smithers, BM ;
Gebski, V ;
Fitzgerald, L ;
Simes, RJ ;
Devitt, P ;
Ackland, S ;
Gotley, DC ;
Joseph, D ;
Millar, J ;
North, J ;
Walpole, ET ;
Denham, JW .
LANCET ONCOLOGY, 2005, 6 (09) :659-668
[8]   Is concurrent radiation therapy required in patients receiving preoperative chemotherapy for adenocarcinoma of the oesophagus? A randomised phase II trial [J].
Burmeister, Bryan H. ;
Thomas, Janine M. ;
Burmeister, Elizabeth A. ;
Walpole, Euan T. ;
Harvey, Jennifer A. ;
Thomson, Damien B. ;
Barbour, Andrew P. ;
Gotley, David C. ;
Smithers, B. Mark .
EUROPEAN JOURNAL OF CANCER, 2011, 47 (03) :354-360
[9]   Posttherapy pathologic stage predicts survival in patients with esophageal carcinoma receiving preoperative chemoradiation [J].
Chirieac, LR ;
Swisher, SG ;
Ajani, JA ;
Komaki, RR ;
Correa, AM ;
Morris, JS ;
Roth, JA ;
Rashid, A ;
Hamilton, SR ;
Wu, TT .
CANCER, 2005, 103 (07) :1347-1355
[10]  
Christein JD, 2002, AM SURGEON, V68, P258